Events

Meet with Christopher Kata and the TrialStat team (booth # 1020), during the SCOPE Summit, February 11th – 14th, in Orlando!

01/18/2024

Meet with Christopher Kata, Director of Sales & Marketing February 11th – 14th, 2024 at the SCOPE Summit for Clinical Operations Executives in Orlando, Florida. Christopher and the TrialStat team are exhibiting in booth # 1020. Christopher Kata, Director of Sales & Marketing905 [email protected] Event: SCOPE – Summit for Clinical Operations Executives When: February 11th…

Read More

Inspiring Women Transforming Science

01/09/2024

“Equity and representation in science matter more than ever, and the Rosalind Franklin Society continues its mission to recognize, foster, and advance the critical contributions of women and underrepresented minorities in science. Our annual year-end conference highlights the innovators and changemakers with unique experiences and leadership.” To learn more about this incredible event and to register for…

Read More

Could an Emerging AI System Lead to Earlier Autism Detection with DT-MRI?

12/12/2023

Excerpt from the Press Release: While a recent report issued by the Centers for Disease Control and Prevention (CDC) noted that 30 percent of children with autism were not diagnosed at eight years of age, emerging research suggests that a combination of artificial intelligence (AI) and diffusion tensor magnetic resonance imaging (DT-MRI) facilitates autism detection…

Read More

Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer

09/14/2023

Alignment with U.S. FDA on design of Phase 2/3 registrational trial, to be initiated in 1Q 2024 Innovative study design allows for potential accelerated approval in untreated (first-line) and previously treated (second-line plus) metastatic bladder cancer Conference call and webcast today at 8 a.m. ET Excerpt from the Press Release: CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle…

Read More

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

09/13/2023

− Topline Results for TAK-279 Show that a Significantly Greater Proportion of Psoriatic Arthritis Patients Achieved at Least an ACR20 Response Compared to Placebo at Week 121 − Based on the Positive Results, Takeda Intends to Initiate a Phase 3 Study of TAK-279 in Psoriatic Arthritis − Full Clinical Results Will be Presented at an…

Read More

Capitalize on The Benefits of Upgrading Your eClinical Technology Today! Meet with Christopher Kata and the TrialStat Team during DIA In Boston June 25th – 29th | Booth #260

06/05/2023

Meet with Christopher Kata, Director of Sales & Marketing and the TrialStat Team on June 25th – 29th! Christopher Kata, Director of Sales & Marketing905 [email protected] When: June 25th – June 29th 2023Where: Boston, MARegistration: DIA Global Annual Meeting 2023 It’s hard to believe an entire year has gone by and we’re ready to meet…

Read More

Meet with Christopher Kata at the “Health Canada Inspectorate Update: 8 Jun 2023” in Mississauga, Ontario.

05/29/2023

Meet with Christopher Kata, Director of Sales & Marketing on June 8th at “Health Canada Inspectorate Update” in Mississauga, Ontario. Christopher Kata, Director of Sales & Marketing905 [email protected] When: June 8th 2023Where: Maple Banquet Hall and Corporate Event Centre, 1325 Eglinton Ave E, Mississauga, ON L4W 4L9Registration: Health Canada Inspectorate Update: 8 Jun 2023 –…

Read More